Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

The FDA approved semaglutide injections sold under the brand name Wegovy in 2021 as a treatment for chronic weight management in patients who have another weight-related condition, such as type 2 ...

Semaglutide has been used for weight loss in clinical trials for up to 104 weeks, or 2 years. Ozempic and Rybelsus are intended for long-term use in managing type 2 diabetes.

Semaglutide is sold as Ozempic, Wegovy, and Rybelsus for type 2 diabetes and weight loss. Injectable versions of the drug need to be refrigerated. Tablets can be stored at room temperature.

References: Jensterle M, Ferjan S, Ležaič L, et al. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes Obes Metab. Published online December ...

Injecting semaglutide may seem a little nerve-wracking at first. But hopefully, now that you have a simple step-by-step guide, you’ll feel more confident and empowered to administer it yourself.

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

The agency said patients should consult with a medical professional on how to measure and administer the correct dose, and that health care providers should "provide patients with the appropriate ...

The new study, which was funded by Novo Nordisk, included about 400 patients with knee osteoarthritis, with an average age of 56, in 11 countries. About 80% of the people in the study were women ...

Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA ...